American Association for Cancer Research
00085472can153393-sup-159431_1_supp_3389441_s3jssx.docx (22.75 kB)

Supplemental Figure legends and Tables from Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

Download (22.75 kB)
journal contribution
posted on 2023-03-31, 00:00 authored by Meghan Morrison Joly, Donna J. Hicks, Bayley Jones, Violeta Sanchez, Monica Valeria Estrada, Christian Young, Michelle Williams, Brent N. Rexer, Dos D. Sarbassov, William J. Muller, Dana Brantley-Sieders, Rebecca S. Cook

Supplemental Figure Legends and Supplemental tables (Table 1 and table 2)



Susan G. Komen for the Cure


National Center for Advancing Translational Sciences




HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activated Akt signaling is well documented in HER2-amplified breast cancer models, but the significance of mTORC2-activated Akt signaling in this setting remains uncertain. We report here that the mTORC2 obligate cofactor Rictor is enriched in HER2-amplified samples, correlating with increased phosphorylation at S473 on Akt. In invasive breast cancer specimens, Rictor expression was upregulated significantly compared with nonmalignant tissues. In a HER2/Neu mouse model of breast cancer, genetic ablation of Rictor decreased cell survival and phosphorylation at S473 on Akt, delaying tumor latency, penetrance, and burden. In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored. We replicated these findings by silencing Rictor in breast cancer cell lines, but not silencing the mTORC1 cofactor Raptor (RPTOR). Taken together, our findings establish that Rictor/mTORC2 signaling drives Akt-dependent tumor progression in HER2-amplified breast cancers, rationalizing clinical investigation of dual mTORC1/2 kinase inhibitors and developing mTORC2-specific inhibitors for use in this setting. Cancer Res; 76(16); 4752–64. ©2016 AACR.